Santarus, Inc. (NASDAQ:SNTS)
CAPS Rating:
A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.
RSS Headlines
Fool UK
Recs
Colitis is a very common problem and there will be a huge demand for this drug world wide. Insurance companies will pay big bucks to get the person off their sick beds and back to work.